duvelisib
Commercial- Indications
- Chronic lymphocytic leukemia, Peripheral T-cell lymphoma
Company intelligence / Profile preview
Secura Bio is an integrated biopharmaceutical company founded in 2019 that develops and commercializes innovative therapies primarily targeting oncology indications such as myeloma, leukemia, glioma, lymphoma, and rare cancers. The company has raised over $100M in funding and operates out of Las Vegas/Henderson, Nevada. Its pipeline includes small molecule therapeutics—particularly antineoplastic agents—and it holds patents related to experimental cancer drugs including HDAC inhibitors. The company’s business model centers around both late-stage clinical development and commercialization of life-changing medicines for patients with serious illnesses.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Secura Bio.